Data di Pubblicazione:
2020
Citazione:
Cell therapy for type 1 diabetes / C. Loretelli, E. Assi, A.J. Seelam, M. Ben Nasr, P. Fiorina. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - (2020). [Epub ahead of print] [10.1080/14712598.2020.1748596]
Abstract:
Introduction: Type 1 diabetes (T1D) is a lifelong condition resulting from autoimmune destruction of insulin-producing β-cells. Islet or whole-pancreas transplantation is limited by the shortage of donors and need for chronic immune suppression. Novel strategies are needed to prevent β-cell loss and to rescue production of endogenous insulin. Areas covered: This review covers the latest advances in cell-based therapies for the treatment and prevention of T1D. Topics include adoptive transfer of cells with increased immunoregulatory potential for β-cell protection, and β-cell replacement strategies such as generation of insulin-producing β-like cells from unlimited sources. Expert opinion: Cell therapy provides an opportunity to prevent or reverse T1D. Adoptive transfer of autologous cells having enhanced immunomodulatory properties can suppress autoimmunity and preserve β-cells. Such therapies have been made possible by a combination of genome-editing techniques and transplantation of tolerogenic cells. In-vitro modified autologous hematopoietic stem cells and tolerogenic dendritic cells may protect endogenous and newly generated β-cells from a patient’s autoimmune response without hampering immune surveillance for infectious agents and malignant cellular transformations. However, methods to generate cells that meet quality and safety standards for clinical applications require further refinement.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Cell therapy; ESC-derived β-cells; HSC therapy; immunotherapy; iPSC-derived β-cells; T1D; tolerogenic dendritic cells; Treg therapy; β-cell replacement
Elenco autori:
C. Loretelli, E. Assi, A.J. Seelam, M. Ben Nasr, P. Fiorina
Link alla scheda completa:
Link al Full Text: